BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chatzisideri T, Leonidis G, Sarli V. Cancer-targeted delivery systems based on peptides. Future Med Chem 2018;10:2201-26. [PMID: 30043641 DOI: 10.4155/fmc-2018-0174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Migliorini F, Cini E, Dreassi E, Finetti F, Ievoli G, Macrì G, Petricci E, Rango E, Trabalzini L, Taddei M. A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery. Chem Commun (Camb) 2022. [PMID: 36043993 DOI: 10.1039/d2cc03052g] [Reference Citation Analysis]
2 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
3 Farshbaf M, Valizadeh H, Panahi Y, Fatahi Y, Chen M, Zarebkohan A, Gao H. The impact of protein corona on the biological behavior of targeting nanomedicines. Int J Pharm 2022;614:121458. [PMID: 35017025 DOI: 10.1016/j.ijpharm.2022.121458] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
4 Radhakrishnan N, Kaul SC, Wadhwa R, Sundar D. Phosphatidylserine Exposed Lipid Bilayer Models for Understanding Cancer Cell Selectivity of Natural Compounds: A Molecular Dynamics Simulation Study. Membranes (Basel) 2022;12:64. [PMID: 35054590 DOI: 10.3390/membranes12010064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chatzisideri T, Leonidis G, Karampelas T, Skavatsou E, Velentza-Almpani A, Bianchini F, Tamvakopoulos C, Sarli V. Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine. J Med Chem 2021. [PMID: 34967607 DOI: 10.1021/acs.jmedchem.1c01468] [Reference Citation Analysis]
6 Rani A, Jakhmola S, Karnati S, Parmar HS, Chandra Jha H. Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections. Tumour Virus Res 2021;12:200227. [PMID: 34800753 DOI: 10.1016/j.tvr.2021.200227] [Reference Citation Analysis]
7 Liu Y, Xia H, Wang Y, Han W, Qin J, Gao W, Qu X, Wang X. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro. Thorac Cancer 2021;12:3053-61. [PMID: 34617400 DOI: 10.1111/1759-7714.14182] [Reference Citation Analysis]
8 Freitas LF, Ferreira AH, Thipe VC, Varca GHC, Lima CSA, Batista JGS, Riello FN, Nogueira K, Cruz CPC, Mendes GOA, Rodrigues AS, Sousa TS, Alves VM, Lugão AB. The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers. Nanomaterials (Basel) 2021;11:2579. [PMID: 34685018 DOI: 10.3390/nano11102579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Front Endocrinol (Lausanne) 2021;12:728088. [PMID: 34539578 DOI: 10.3389/fendo.2021.728088] [Reference Citation Analysis]
10 Khatami F, Matin MM, Danesh NM, Bahrami AR, Abnous K, Taghdisi SM. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21. Carbohydr Polym 2021;266:118111. [PMID: 34044928 DOI: 10.1016/j.carbpol.2021.118111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chatzisideri T, Dalezis P, Leonidis G, Bousis S, Trafalis D, Bianchini F, Sarli V. Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins. Future Med Chem 2021;13:877-95. [PMID: 33858195 DOI: 10.4155/fmc-2020-0309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Gilad Y, Gellerman G, Lonard DM, O'Malley BW. Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations. Cancers (Basel) 2021;13:669. [PMID: 33562300 DOI: 10.3390/cancers13040669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Borbély A, Pethő L, Szabó I, Al-Majidi M, Steckel A, Nagy T, Kéki S, Kalló G, Csősz É, Mező G, Schlosser G. Structural Characterization of Daunomycin-Peptide Conjugates by Various Tandem Mass Spectrometric Techniques. Int J Mol Sci 2021;22:1648. [PMID: 33562082 DOI: 10.3390/ijms22041648] [Reference Citation Analysis]
14 Anselmi M, Borbély A, Figueras E, Michalek C, Kemker I, Gentilucci L, Sewald N. Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates. Chemistry 2021;27:1015-22. [PMID: 32955139 DOI: 10.1002/chem.202003471] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huang F, Shu Q, Qin Z, Tian J, Su Z, Huang Y, Gao M. Anticancer Actions of Azurin and Its Derived Peptide p28. Protein J 2020;39:182-9. [PMID: 32180097 DOI: 10.1007/s10930-020-09891-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Taghdisi SM, Danesh NM, Nameghi MA, Bahreyni A, Ramezani M, Alibolandi M, Emrani AS, Abnous K. Co-delivery of doxorubicin and α-PCNA aptamer using AS1411-modified pH-responsive nanoparticles for cancer synergistic therapy. Journal of Drug Delivery Science and Technology 2020;58:101816. [DOI: 10.1016/j.jddst.2020.101816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Xia X, Yang X, Huang P, Yan D. ROS-Responsive Nanoparticles Formed from RGD-Epothilone B Conjugate for Targeted Cancer Therapy. ACS Appl Mater Interfaces 2020;12:18301-8. [PMID: 32242653 DOI: 10.1021/acsami.0c00650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
18 Vásquez P, Vidal F, Torres J, Jiménez VA, Guzmán L. Rational Design and In Vitro Evaluation of Novel Peptides Binding to Neuroligin-1 for Synaptic Targeting. J Chem Inf Model 2020;60:995-1004. [PMID: 31876421 DOI: 10.1021/acs.jcim.9b01003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Larocca AV, Toniolo G, Tortorella S, Krokidis MG, Menounou G, Di Bella G, Chatgilialoglu C, Ferreri C. The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity. Molecules 2019;24:E3085. [PMID: 31450691 DOI: 10.3390/molecules24173085] [Reference Citation Analysis]
20 Farzipour S, Hosseinimehr SJ. Correlation between in vitro and in vivo Data of Radiolabeled Peptide for Tumor Targeting. MRMC 2019;19:950-60. [DOI: 10.2174/1389557519666190304120011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Borbély A, Figueras E, Martins A, Bodero L, Raposo Moreira Dias A, López Rivas P, Pina A, Arosio D, Gallinari P, Frese M, Steinkühler C, Gennari C, Piarulli U, Sewald N. Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen 2019;8:737-42. [PMID: 31275795 DOI: 10.1002/open.201900110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
22 Figueras E, Martins A, Borbély A, Le Joncour V, Cordella P, Perego R, Modena D, Pagani P, Esposito S, Auciello G, Frese M, Gallinari P, Laakkonen P, Steinkühler C, Sewald N. Octreotide Conjugates for Tumor Targeting and Imaging. Pharmaceutics 2019;11:E220. [PMID: 31067748 DOI: 10.3390/pharmaceutics11050220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sartori A, Corno C, De Cesare M, Scanziani E, Minoli L, Battistini L, Zanardi F, Perego P. Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. Cancers (Basel) 2019;11:E531. [PMID: 31013908 DOI: 10.3390/cancers11040531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
24 Borbély A, Figueras E, Martins A, Esposito S, Auciello G, Monteagudo E, Di Marco A, Summa V, Cordella P, Perego R, Kemker I, Frese M, Gallinari P, Steinkühler C, Sewald N. Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery. Pharmaceutics 2019;11:E151. [PMID: 30939768 DOI: 10.3390/pharmaceutics11040151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Raposo Moreira Dias A, Pina A, Dean A, Lerchen HG, Caruso M, Gasparri F, Fraietta I, Troiani S, Arosio D, Belvisi L, Pignataro L, Dal Corso A, Gennari C. Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate. Chemistry 2019;25:1696-700. [PMID: 30452790 DOI: 10.1002/chem.201805447] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]